Charles Schwab
NVIV

Charles Schwab’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Charles Schwab’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3
Closed -$237K – 3177
2017
Q1 		$237K Hold
3
– – ﹤0.01% 2900
2016
Q4 		$246K Hold
3
– – ﹤0.01% 2911
2016
Q3 		$398K Hold
3
– – ﹤0.01% 2700
2016
Q2 		$338K Buy
3
+1
+50% +$118K ﹤0.01% 2742
2016
Q1 		$262K Hold
2
– – ﹤0.01% 2817
2015
Q4 		$270K Hold
2
– – ﹤0.01% 2896
2015
Q3 		$324K Hold
2
– – ﹤0.01% 2796
2015
Q2 		$606K Buy
+2
New +$529K ﹤0.01% 2615

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab's NVIV Position: Q2 2017 in Review

Charles Schwab sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2017, closing a stake of 3 shares — an estimated $237K sold.

Charles Schwab first reported a position in NVIV in Q2 2015 and held it in 8 quarters. The position peaked at $606K in Q2 2015. 37 funds tracked by Wall St. Rank hold NVIV as of Q2 2017.

  • Charles Schwab reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2017 after selling out during the quarter.
  • Charles Schwab sold 3 InVivo Therapeutics Holdings Corp shares in Q2 2017, an estimated $237K.
  • Charles Schwab first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 8 quarters.
  • Charles Schwab's InVivo Therapeutics Holdings Corp position peaked at $606K in Q2 2015.
  • 37 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2017.

Based on Charles Schwab's 13F filing for Q2 2017, filed 2 Aug 2017.